A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a ...

Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda.

The National Institute for Health and Care Excellence (NICE) has recommended brentuximab vedotin combined with doxorubicin, ...

The study included patients who were heavily pre-treated, some of whom had received prior CAR-T therapy, and survival benefit was observed irrespective of CD30 expression. The ECHELON-3 study ...

Patients on Adcetris and chemo had better progression-free and overall survival after six years of follow-up compared to those on chemo only.

From today, adults with advanced Hodgkin lymphoma have access to a new treatment, after we recommended brentuximab vedotin (brand name Adcetris) in combination with other therapies for routine NHS use ...

The UK’s health technology assessor the National Institute for Health and Care Excellence (NICE) has recommended brentuximab ...

Takeda UK has announced that the National Institute for Health and Care Excellence (NICE) has recommended Adcetris ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response ...